Lyell Immunopharma (LYEL) Price & Analysis

Compare

146 Followers

LYEL Stock Chart & Stats

$17.51

-$0.01(-1.66%)

At close: Jan 08 4:00 PM EST

$17.51

-$0.01(-1.66%)

Day’s Range― - ―

52-Week Range$7.65 - $29.98

Previous CloseN/A

Volume124.06K

Average Volume (3M)56.64K

Market Cap

$306.42M

Enterprise Value-$99.42M

Total Cash (Recent Filing)$276.79M

Total Debt (Recent Filing)$46.60M

Price to Earnings (P/E)―

Beta1.99

Next Earnings

Nov 11, 2025

EPS Estimate

-2.64

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.89

Shares Outstanding19,211,203

10 Day Avg. Volume34,655

30 Day Avg. Volume56,642

Financial Highlights & Ratios

PEG Ratio-0.24

Price to Book (P/B)8.74

Price to Sales (P/S)54867.93

P/FCF Ratio-20.55

Enterprise Value/Market Cap-0.32

Enterprise Value/Revenue-1.66K

Enterprise Value/Gross Profit-1.66K

Enterprise Value/Ebitda0.50

Forecast

1Y Price Target

$14.00

Price Target Upside-20.05% Downside

Rating ConsensusHold

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

EfficacyLYL314 has shown promising early complete responses lasting at least 6 months, equating to ~51% of all treated patients maintaining durable complete responses for six months.

SafetySafety looks encouraging, with no Grade 3+ cytokine release syndrome and 14% Grade 3 immune effector cell-associated neurotoxicity syndrome that resolve relatively quickly.

Bears Say

CompetitionIncreasing competition among CAR-T products for B cell lymphomas as well as personnel changes at the FDA may increase the risk of clinical development.

Lyell Immunopharma News

LYEL Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Lyell Immunopharma, Inc. (LYEL) is scheduled to report 3rd quarter earnings on 11/11/2025. Regarding Q3 estimates, Wall Street...

14m ago

LYEL

Lyell Immunopharma Appoints New Financial Leadership Team

Lyell Immunopharma ( ($LYEL) ) just unveiled an update. On October 31, 2025, Lyell Immunopharma announced key leadership...

6d ago

LYEL

Lyell Immunopharma’s LYL314 Study: A Promising Step in Lymphoma Treatment

Lyell Immunopharma, Inc. (($LYEL)) announced an update on their ongoing clinical study. Lyell Immunopharma, Inc. is conducting a...

12d ago

LYEL

Lyell Immunopharma’s New CAR T-Cell Therapy Trial: A Potential Game-Changer in Lymphoma Treatment?

Lyell Immunopharma, Inc. (($LYEL)) announced an update on their ongoing clinical study. Lyell Immunopharma, Inc. is conducting a...

13d ago

LYEL

Lyell Immunopharma initiated with a Buy at Lucid Capital

Lucid Capital analyst Christopher Liu initiated coverage of Lyell Immunopharma (LYEL) with a Buy rating and $20 price...

1M ago

LYEL

Lyell Immunopharma CFO Resignation Announced

Lyell Immunopharma ( ($LYEL) ) has issued an update. On September 15, 2025, Charles Newton announced his resignation...

2M ago

LYEL

Lyell announces initiation of Phase 3 head-to-head CAR T-cell therapy trial

Lyell Immunopharma (LYEL) announced the initiation of PiNACLE – H2H, a Phase 3 head-to-head CAR T-cell therapy randomized...

2M ago

LYEL

Lyell Immunopharma Advances CAR T-Cell Therapies

Lyell Immunopharma, Inc. ( ($LYEL) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

LYEL

Lyell Immunopharma trading resumes

09:54 EDT Lyell Immunopharma (LYEL) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

3M ago

LYEL

Lyell Immunopharma trading halted, volatility trading pause

09:49 EDT Lyell Immunopharma (LYEL) trading halted, volatility trading pause Published first on TheFly – the ultimate source...

3M ago

LYEL

Lyell Immunopharma files to sell 3.75M shares of common stock for holders

16:50 EDT Lyell Immunopharma (LYEL) files to sell 3.75M shares of common stock for holders Published first on...

3M ago

LYEL

Lyell Immunopharma Secures $100 Million in Private Placement

Lyell Immunopharma ( ($LYEL) ) just unveiled an update. On July 24, 2025, Lyell Immunopharma entered into a...

4M ago

LYEL

Lyell Immunopharma announces up to $100M equity private placement

Lyell Immunopharma (LYEL) entered into a securities purchase agreement for a private placement with certain institutional and other...

4M ago

LYEL

Lyell Immunopharma files to sell 625,000 shares of common stock for holders

22:21 EDT Lyell Immunopharma (LYEL) files to sell 625,000 shares of common stock for holders Published first on...

4M ago

LYEL

LYEL FAQ

What was Lyell Immunopharma’s price range in the past 12 months?

Lyell Immunopharma lowest stock price was $7.65 and its highest was $29.98 in the past 12 months.

What is Lyell Immunopharma’s market cap?

Lyell Immunopharma’s market cap is $306.42M.

When is Lyell Immunopharma’s upcoming earnings report date?

Lyell Immunopharma’s upcoming earnings report date is Nov 11, 2025 which is in 2 days.

How were Lyell Immunopharma’s earnings last quarter?

Lyell Immunopharma released its earnings results on Aug 12, 2025. The company reported -$2.89 earnings per share for the quarter, beating the consensus estimate of -$3.52 by $0.63.

Is Lyell Immunopharma overvalued?

According to Wall Street analysts Lyell Immunopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lyell Immunopharma pay dividends?

Lyell Immunopharma does not currently pay dividends.

What is Lyell Immunopharma’s EPS estimate?

Lyell Immunopharma’s EPS estimate is -2.64.

How many shares outstanding does Lyell Immunopharma have?

Lyell Immunopharma has 19,211,203 shares outstanding.

What happened to Lyell Immunopharma’s price movement after its last earnings report?

Lyell Immunopharma reported an EPS of -$2.89 in its last earnings report, beating expectations of -$3.52. Following the earnings report the stock price went up 2.46%.

Which hedge fund is a major shareholder of Lyell Immunopharma?

Currently, no hedge funds are holding shares in LYEL

Lyell Immunopharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

-76.59%

Trailing 12-Months

Asset Growth

-41.08%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Lyell Immunopharma

Lyell Immunopharma (LYEL) is a biotechnology company focused on developing innovative cell therapies to treat cancer, particularly solid tumors. The company operates within the biopharmaceutical sector and utilizes its proprietary technology platform to engineer T cells for enhanced anti-tumor activity. Lyell's core products include a pipeline of cell therapy candidates aimed at improving the efficacy and safety of cancer treatments, leveraging advancements in immunotherapy.

Lyell Immunopharma (LYEL) Earnings & Revenues

Historic Earnings Reports

LYEL Stock 12 Month Forecast

Average Price Target

$14.00

▼(-20.05% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","26":"$26","11.75":"$11.75","16.5":"$16.5","21.25":"$21.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,11.75,16.5,21.25,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.66,16.916923076923077,17.173846153846153,17.43076923076923,17.68769230769231,17.944615384615386,18.201538461538462,18.45846153846154,18.715384615384615,18.97230769230769,19.229230769230767,19.486153846153847,19.743076923076924,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.66,16.455384615384617,16.25076923076923,16.046153846153846,15.841538461538462,15.636923076923077,15.432307692307692,15.227692307692308,15.023076923076923,14.818461538461538,14.613846153846154,14.409230769230769,14.204615384615385,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.66,16.147692307692306,15.635384615384616,15.123076923076923,14.61076923076923,14.098461538461539,13.586153846153845,13.073846153846153,12.561538461538461,12.04923076923077,11.536923076923078,11.024615384615384,10.512307692307692,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.6,"date":1727740800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.4,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":12.8,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.22,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.69,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.22,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.42,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.02,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.41,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.55,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >